CHMP Backs Galcanezumab for Migraine Prevention

The EMA committee has recommended marketing authorization for a second CGRP antagonist for migraine prevention, following its first-in-class approval recommendation for erenumab in May.
Medscape Medical News

Source link

Related posts

Non-invasive monitoring of alternative splicing outcomes to identify candidate therapies for myotonic dystrophy type 1


Author response: Subcutaneous ofatumumab in patients with relapsing-remitting multiple sclerosis: The MIRROR study


What is pregabalin?


This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. Accept Read More

Privacy & Cookies Policy